Please assess the completion status of the following clinical trial:

Trial Title: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~1. Confirmed diagnosis of CLL or SLL that meets the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria~2. CLL/SLL requiring treatment per 2008 IWCLL criteria~3. Relapsed or refractory to at least 1 prior systemic therapy for CLL/SLL~4. Measurable disease by Computerized Tomography (CT)/magnetic resonance imaging (MRI)~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~6. Life expectancy ≥ 6 months~7. Adequate bone marrow function~8. Adequate renal and hepatic function~Key Exclusion Criteria~1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation~2. Clinically significant cardiovascular disease.~3. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast~4. History of severe bleeding disorder or history of spontaneous bleeding requiring blood transfusion or other medical intervention~5. History of stroke or intracranial hemorrhage within 180 days before first dose of study drug~6. Severe or debilitating pulmonary disease~7. Active fungal, bacterial, and/or viral infection requiring systemic therapy~8. Known central nervous system involvement by leukemia or lymphoma~9. Known infection with HIV or active viral hepatitis B or C infection~10. Moderate or severe hepatic impairment, ie, Child-Pugh class B or C~11. Major surgery within 4 weeks of the first dose of study drug~12. Prior treatment with a (Burton's Kinase) BTK inhibitor~13. Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1~14. Pregnant or lactating women~15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug~16. Hypersensitivity to zanubrutinib, ibrutinib, or any of the other ingredients in either drug~17. Concurrent participation in another therapeutic clinical trial~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib (Type: EXPERIMENTAL): Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy
- Ibrutinib (Type: ACTIVE_COMPARATOR): Participants received Ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy

Based on this trial design, predict the completion outcome and termination type (if applicable).